Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
Hyun Jung Kim1,2, Sukmook Lee3, Yong-Seok Oh4
1Research Institute, National Cancer Center, Goyang-si, South Korea.
Abstract:
Current chemotherapy regimens have certain limitations in improving the survival rates of patients with advanced ovarian cancer. Hepatocyte growth factor (HGF) is important in ovarian cancer cell migration and invasion. This study assessed the effects of YYB-101, a humanized monoclonal anti-HGF antibody, on the growth and metastasis of ovarian cancer cells. YYB-101 suppressed the phosphorylation of the HGF receptor c-MET and inhibited the migration and invasion of SKOV3 and A2780 ovarian cancer cells. Moreover, the combination of YYB-101 and paclitaxel synergistically inhibited tumor growth in an in vivo ovarian cancer mouse xenograft model and significantly increased the overall survival (OS) rate compared with either paclitaxel or YYB-101 alone. Taken together, these findings suggest that YYB-101 has therapeutic potential in ovarian cancer when combined with conventional chemotherapy agents.
Insights
A new antibody therapy, YYB-101, targeting hepatocyte growth factor (HGF), shows promise for advanced ovarian cancer. Combined with chemotherapy, it significantly improved survival in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Advanced ovarian cancer survival rates are limited by current chemotherapy.
- Hepatocyte growth factor (HGF) plays a critical role in ovarian cancer cell migration and invasion.
Purpose of the Study:
- To evaluate the efficacy of YYB-101, a humanized monoclonal anti-HGF antibody, in inhibiting ovarian cancer growth and metastasis.
- To assess the combined therapeutic effect of YYB-101 and paclitaxel in ovarian cancer models.
Main Methods:
- Assessed YYB-101's effect on HGF receptor c-MET phosphorylation in ovarian cancer cells (SKOV3, A2780).
- Evaluated YYB-101's impact on cancer cell migration and invasion in vitro.
- Tested the synergistic effect of YYB-101 and paclitaxel in an in vivo ovarian cancer mouse xenograft model.
Main Results:
- YYB-101 effectively suppressed c-MET phosphorylation and inhibited ovarian cancer cell migration and invasion.
- The combination of YYB-101 and paclitaxel demonstrated synergistic inhibition of tumor growth.
- Combined therapy significantly increased overall survival (OS) compared to single-agent treatments.
Conclusions:
- YYB-101 exhibits therapeutic potential for ovarian cancer by targeting the HGF/c-MET pathway.
- Combining YYB-101 with conventional chemotherapy, such as paclitaxel, offers a promising strategy to improve treatment outcomes for advanced ovarian cancer.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
12:42Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Feedback Inhibition